CliffBio
small molecule

PACLITAXEL

PACLITAXEL

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand namePACLITAXEL
Active ingredientPACLITAXEL
Strength100MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2025
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

PACLITAXEL patent cliff — loss of exclusivity — | CliffBio